93 related articles for article (PubMed ID: 8780933)
21. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
[TBL] [Abstract][Full Text] [Related]
22. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
[TBL] [Abstract][Full Text] [Related]
23. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
24. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
[TBL] [Abstract][Full Text] [Related]
25. Expression and significance of P53 protein and MDM-2 protein in human gliomas.
Wang AL; Liu ZX; Li G; Zhang LW
Chin Med J (Engl); 2011 Aug; 124(16):2530-3. PubMed ID: 21933600
[TBL] [Abstract][Full Text] [Related]
26. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.
Jiang M; Shao ZM; Wu J; Lu JS; Yu LM; Yuan JD; Han QX; Shen ZZ; Fontana JA
Int J Cancer; 1997 Oct; 74(5):529-34. PubMed ID: 9355976
[TBL] [Abstract][Full Text] [Related]
27. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
28. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression.
Kouvidou C; Stefanaki K; Dai Y; Tzardi M; Koutsoubi K; Darivianaki K; Karidi E; Rontogianni D; Zois E; Kakolyris S; Georgoulias V; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2615-9. PubMed ID: 9252690
[TBL] [Abstract][Full Text] [Related]
29. [Relationship of PTEN, Mdm2 and p53 expression in astrocytoma].
Zhong XY; Sun YH; Chen YX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):478-81. PubMed ID: 14575575
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
31. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
32. mdm-2 oncoprotein expression associated with deletion of the long arm of chromosome 12 in a case of mantle cell lymphoma with blastoid transformation [corrected].
Haidar JH; Neiman RS; Orazi A; Albitar M; McCarthy LJ; Heerema N
Mod Pathol; 1996 Apr; 9(4):355-9. PubMed ID: 8729971
[TBL] [Abstract][Full Text] [Related]
33. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance.
Haidar MA; El-Hajj H; Bueso-Ramos CE; Manshouri T; Glassman A; Keating MJ; Maher A
Am J Hematol; 1997 Mar; 54(3):189-95. PubMed ID: 9067496
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.
Olson DC; Marechal V; Momand J; Chen J; Romocki C; Levine AJ
Oncogene; 1993 Sep; 8(9):2353-60. PubMed ID: 7689721
[TBL] [Abstract][Full Text] [Related]
35. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
36. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas.
Kordek R; Biernat W; Debiec-Rychter M; Alwasiak J; Liberski PP
Pathol Res Pract; 1996 Mar; 192(3):205-9. PubMed ID: 8739466
[TBL] [Abstract][Full Text] [Related]
38. Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors.
Bian XW; Shi JQ; Liu FX
Anal Quant Cytol Histol; 2000 Dec; 22(6):429-37. PubMed ID: 11147296
[TBL] [Abstract][Full Text] [Related]
39. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
40. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas.
Seki A; Kodama J; Miyagi Y; Kamimura S; Yoshinouchi M; Kudo T
Int J Cancer; 1997 Sep; 73(1):33-7. PubMed ID: 9334806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
